Company: Management

 

MANAGEMENT TEAM

The Tribiosys Business Management Team has significant expertise in the biopharmaceutical, healthcare and systems integration verticals. In the course of their careers, the team has successfully delivered mission-critical, enterprise-wide, supply chain optimization solutions to over a hundred Fortune 500 companies.

Samir Bhatia, M.S.
Principal

ADVISORY BOARD

The Tribiosys Advisory Board is composed of several industry leaders.

Richard W. Barker, D.Phil.

Madhav Anand, M.S.

Ramesh Shivdasani, M.D., Ph.D.

Vikrant Raina, M.B.A.

Joseph S. Gentile, M.S.

Shiv Tasker, MBA

Susan J. Ward, Ph.D.



MANAGEMENT TEAM  


Samir Bhatia, M.S.
Principal

Mr. Bhatia has over 15 years of experience in technology based companies. Mr. Bhatia is responsible for Operations and Partnerships at Tribiosys. Before joining Tribiosys, Mr. Bhatia was founder and CTO of StructuredMarkets, Inc., an online equity marketplace. At Systems Engineering Associates, Mr. Bhatia managed Internet/e-commerce project marketing and sales. Prior to SEA, Samir managed the turnaround of Xscribe Corporation, as general manager overseeing product design and development, sales and marketing, and support functions. Mr. Bhatia has a MS degree in Computer Science and an MS degree in Physics from Northeastern University.


ADVISORY BOARD


Richard Barker, D.Phil.

   
Dr. Barker has over a decade of experience managing health care and medical informatics organizations. Dr. Barker held executive committee positions at Chiron, a $900 million biopharmaceutical company. His first position was as president and chief executive of Chiron's largest division, the $600m diagnostics business, before its sale to Bayer Corporation. Subsequently, he served as senior vice president responsible for corporate strategy and business development, including M&A and technology licensing. Before Chiron, Dr. Barker developed healthcare IT solutions as general manager of IBM's $2B worldwide healthcare business. Previously, Dr. Barker led McKinsey & Company's European healthcare practice. Dr. Barker sits on the Boards of Sunquest Information Systems (a laboratory information company) and EXACT Sciences, an applied genomics company. He received a BA in Chemistry and DPhil in Biophysics, both from Oxford University, UK.
                                                                                                                                                  Top



Madhav Anand, M.S.

Mr. Anand has over 12 years of experience in business strategy, business process, information technology, and data management systems consulting. Before founding Tribiosys, Mr. Anand was a founding partner at Usheron Ventures, LLC, a provider of funding and strategic guidance to technology start-ups. Prior to Usheron, Mr. Anand was the president and founder of International Integration, Inc. (NASDAQ: ICUB), which merged with Razorfish, Inc. (NASDAQ: RAZF) in November 1999. At the time of the merger, I-Cube had $70 million in revenues, with 600 consultants and 6 offices across the United States and Europe. Mr. Anand holds a MS in Computer Science from Northeastern University.

                                                                                                                                                  
Top


Ramesh Shivdasani, M.D., Ph.D.

Dr. Shivdasani is an assistant professor of Medicine at Dana-Farber Cancer Institute and Harvard Medical School. His training includes Internal Medicine at Brigham & Women's Hospital, Medical Oncology at the Dana-Farber Cancer Institute, and post-doctoral research training at Children's Hospital in Boston. His current research on the molecular basis of mammalian development and cell differentiation is funded through the National Institutes of Health and charitable foundations. A member of several professional societies, Dr. Shivadasani has published many original papers and is board certified in Internal Medicine and Medical Oncology. He holds MD and PhD degrees from the University of Michigan.

                                                                                                                                                  Top



Vikrant Raina, M.B.A.

Mr. Raina is a director of Boston Ventures, LP, a private equity firm located in Boston, MA. Previous to joining Boston Ventures, Mr. Raina served as executive director in the Communications, Media and Technology group at Goldman Sachs (Asia), LLC. Prior to that, Mr. Raina worked in the Communications and High Technology practice for The Boston Consulting Group, Inc. He holds a BS degree from Yale University and a MBA with distinction from Harvard Graduate School of Business Administration.

                                                                                                                                                 Top





 Joseph Gentile, M.S.

Mr. Gentile, Vice President and General Manager of BD Biosciences Discovery Labware, has over 20 years of experience in the high-technology medical device and life sciences industry. He was responsible for the strategic and operational restructuring of the company by re-focusing the business on the higher growth areas of drug discovery and proteomics while further developing, revitalizing and strengthening the core business of tissue culture and fluid handling. As a member of the BD Biosciences Leadership Team, he has joint responsibility for overall business performance and development including, business alliances, acquisitions and portfolio management. Prior to joining BD (Becton, Dickinson and Company), of which BD Biosciences is one of four business segments, Mr. Gentile served as a member of Hewlett-Packard's core management team responsible for the determination of customer needs, product requirements and business structure for a major new business start up. During his tenure with Hewlett-Packard, he was responsible for the design and implementation of the Medical Group's Global Technology Strategy and management of a group-wide task force chartered with the design of a comprehensive resource allocation model for project, program and portfolio valuation. Mr. Gentile graduated from Northeastern University with a Bachelor of Science in electrical engineering and a minor in biology. He received a Master of Science and a Master of Business Administration, graduating Summa Cum Laude, from Boston University.


                                                                                                                                                  Top


Shiv Tasker, M.B.A.

Shiv Tasker, a partner with Emsan Consulting, heads the start up and emerging growth company practice with focus on business and marketing strategy.  Prior to Emsan Consulting, Shiv was the president and CEO of Phase Forward, a software and service solution vendor for the data collection and management of clinical trials of new drugs and devices.  

Prior to Phase Forward, Shiv was Sr. Vice President for Worldwide Sales, Consulting Services and Corporate Marketing at Viewlogic Systems Inc, a supplier of complex electronic design automation tools for Integrated Circuit and Printed Circuit Board design.  As SVP of Sales, Viewlogic had successive quarters of record growth ($200M run rate) till the company’s sale to a larger competitor.  He improved service gross margins from 27% to 62% within 6 quarters and successfully branded the company away from its historical slower growing products to a new set of hot growth products that led to the company being viewed as a serious acquisition target.

Mr. Tasker spent 8 years at Cadence Design Systems in a variety of roles in marketing and general management with ever increasing responsibility for product lines and larger P&Ls.  Prior to Cadence, he was with Intergraph Corp for 5.5 years, initially as a programmer and later as a marketer.

Mr. Tasker holds an MBA from the University of Texas at Arlington and a BS from the University of Bombay in Statistics and Economics. He is a member of the Drug Information Association and works with the Youth Technology Entrepreneurs, a non-profit organization aimed at enriching high school curriculums with real life technology skills – primarily in lower income school districts.  He was recently honored by Mass Hi-Tech as an All-Star.

                                                                                                                                                  Top



Susan J. Ward, Ph.D.

Executive Advisor to Biotech, their Investors and Suppliers
Dr. Ward has over 20 years operational experience in major Pharma and as a corporate office in successful Biotech, with responsibilities in drug discovery and development, supporting technology and process development, and corporate strategy.

Educated as a research scientist in central nervous system disorders, Susan began her research career at Sterling Drug in 1982. In 1993, she joined Wyeth Research as Vice President of Research (UK) and Vice President of CNS Disorders worldwide. Adopting responsibility for Project Management and the Wyeth Drug Development Portfolio in 1996, Susan oversaw the development of 30+ new and life cycle extension products, including global approvals for Enbrel, Mylotarg, Sonata, Rapamune and Protonix, and label extensions for Efexor and Women’s Health products. She established one of the first project management capabilities in drug discovery in the industry, halving time to first studies in man, and improving productivity in several steps in the development process.

Joining the corporate senior team of Millennium Pharmaceuticals Inc. in 2000, Susan led the evolution of Millennium’s successful genome technology platform into downstream R&D areas, established knowledge management capability, and integrated these into a comprehensive Productivity strategy and platform. Susan worked with Infinity Pharmaceuticals, first as an advisor to its inception and early start-up, and than as Executive Vice President establishing a cutting-edge and integrated platform operational and strategic platform designed to aid productivity of both scientists and business functions.

Dr. Ward is now an Executive Advisor to Biotechnology, sometimes joining the senior management team of a company at a strategic transition point for an interim period of time. She is the founding CSO of ThoughLynx, a software company dynamically integrating disparate information sources for the Life Sciences, and serves on the Advisory Boards of Timeblaster, Ingenuity, and Business Engine software companies. Susan established the initial research strategy and plan for Alnylam Pharmaceuticals, a leading RNA-interference company, and undertakes shorter consults in Biotech, recent clients including Viropharma, Adolor, Structural Genomics, and several venture capital firms.

                                                                                                                  
                                                                                                                                                  Top


                                                                                                                                     

 
© Tribiosys.com 2004-2006 - All rights reserved